1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Zenlabs Ethica Ltd

Zenlabs Ethica Ltd

BBSE:ZENLABS
26.95
INR
+0.61
(+2.32%)
-3.94EPS
211.60MMarket Cap
Zenlabs Ethica Ltd
BSE:ZENLABS
(Bombay Stock Exchange)

Recent

price

26.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
38.82
9.45
- -
- -
- -
24.2
124.67
110.35
103.37
92.09
87
106.13
102.74
89.96
78.99
72.08
76.98
Revenue per Share
-1.84
-2.81
-0.17
-0.15
-0.17
0.06
1.46
1.79
1.94
-1.13
1.18
1.2
0.75
0.65
0.41
-2.97
-3.94
Basic EPS, GAAP
- -
-0.64
-0.01
-0.03
0.05
-1.18
-1.66
0.5
0.64
0.61
-13.87
-0.59
2.33
-13.92
5.89
6.24
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.25
- -
- -
- -
- -
Dividend per Share
- -
5.72
5.54
5.4
5.17
7.35
8.9
10.77
12.71
11.38
13.16
14.34
14.91
15.55
16.01
13.08
- -
Book Value per Share
- -
5.72
5.54
5.4
5.17
7.35
8.9
10.77
12.71
11.38
13.16
14.34
14.91
15.55
16.01
13.08
- -
Tangible Book Value per Share
4
4
4
4
4
7
7
7
7
7
7
7
7
7
7
7
6
Basic Weighted Avg Shares
148
36
- -
- -
- -
158
812
718
673
599
566
691
669
586
514
469
496
Sales/Revenue/Turnover
-4.73
-29.71
- -
- -
- -
2.49
1.54
2.58
2.77
-1.63
1.83
2.18
2.48
1.91
2.55
2.27
0.49
Operating Margin (%)
- -
- -
- -
- -
- -
1
2
2
2
3
7
9
13
13
13
9
7
Depreciation Expense
-7
-11
-1
-1
-1
2
10
12
13
-7
8
8
5
4
3
-19
-25
Net Income, GAAP
- -
- -
- -
- -
- -
- -
22.5
29.63
33.15
- -
10.77
35.95
27.46
27.57
37.09
- -
- -
Effective Tax Rate (%)
-4.73
-29.77
- -
- -
- -
1.08
1.17
1.62
1.88
-1.22
1.35
1.13
0.73
0.72
0.52
-4.13
-5.12
Profit Margin (%)
- -
21
20
20
-12
28
40
54
68
59
60
82
80
85
92
80
- -
Working Capital
- -
- -
- -
- -
- -
9
6
4
3
3
19
21
30
16
6
5
- -
LT Debt
- -
22
21
20
20
48
58
70
83
74
86
93
97
101
104
85
- -
Total Equity
- -
- -
- -
- -
- -
- -
14.61
15.47
13.86
- -
8.99
7.83
5.4
4.72
3.44
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
16.29
16.76
15.64
- -
10.16
8.33
6.07
4.94
3.49
- -
- -
Return on Capital (%)
- -
- -
-3.04
-2.72
-3.31
1.1
17.99
18.18
16.53
-9.34
9.61
8.74
5.14
4.25
2.62
-20.44
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
105
- -
LT Borrowings
- -
2
- -
LT Finance Leases
- -
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
6
Market Capitalization
130
113
212

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
351
- -
Cash, Cash Equivalents & STI
- -
31
- -
Accounts Receivable, Net
- -
157
- -
Inventories
- -
150
- -
Total Current Liabilities
- -
271
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
105
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.71%
0.38%
-18.33%
Free Cash Flow
-384.63%
-285.2%
6.06%
Net Income, GAAP
-77.74%
-180.91%
-819.02%
Sales/Revenue/Turnover
36.64%
-2.92%
-8.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
124
134
127
130
514
2026
115
124
124
106
469
2027
142
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.06
0.08
0.13
0.14
0.41
2026
0.05
0.06
-3.08
- -
-2.97
2027
-0.88
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
Zenlabs Ethica Limited, a WHO-GMP certified pharmaceutical company headquartered in Chandigarh, India, and founded in 1993, engages primarily in the marketing, distribution and third-party manufacturing of branded pharmaceutical formulations across multiple therapeutic segments in India and select international markets including Myanmar, Indonesia, Malaysia, Thailand, Cambodia, Vietnam, Laos, Philippines, Singapore, Brunei and Timor-Leste. The company operates through three key divisions--Zenlabs, Coles Pharma and Mega Star--offering an extensive portfolio exceeding 1,000 brands that encompasses analgesics and anti-inflammatory drugs; skin preparations; neurological disorder treatments; ear, eye and nasal drops; anti-diabetic medications; anti-depressants; anti-infectives; anti-emetics; steroids and anabolic steroids; anti-hypertensive drugs; anti-allergic, anti-cold and cough syrups; nutraceuticals; antacids, enzymes and appetite stimulants; ayurvedic preparations; GIT disorder remedies; soaps and dusting powders; and other pharmaceutical drugs including tablets, capsules (beta-lactam and non-beta-lactam antibiotics), ointments, external preparations, oral liquids, dry syrups, ophthalmic preparations, injectables, soft gelatin capsules and private-label products tailored for anti-obesity, anti-bacterial, anti-fungal, pain killers and nutritional supplements. As part of the Preet Remedies Group, Zenlabs Ethica leverages five manufacturing units--Preet Remedies Pvt. Ltd., Oasis Pharma & Phytomolecules Pvt. Ltd., Quixotic Healthcare Units I & II, and Alpha Products--for state-of-the-art production compliant with FDA norms and GMP practices, supported by advanced warehouses, quality control labs and a robust distribution network. Launched in collaboration with Zenlabs Pharmaceutical Inc. of Canada, the company recently ventured into diversified segments like neurology and cytrics in 2023, held its 32nd Annual General Meeting on September 29, 2025, approved unaudited financial results for quarters ended June 30, 2025, September 30, 2025, and March 31, 2025 through board meetings in August, September and November 2025 respectively, and continues routine corporate governance activities including trading window closures amid a board meeting scheduled for November 8, 2025 to review half-year results.